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Summary Forty-three children with malignant soft tissue sarcomas (IRS Groups II-IV) were treated with a
rapid dose delivery chemotherapy protocol comprising six courses of vincristine, adriamycin and cyclophos-
phamide, given in most cases within 8 weeks (Rapid VAC). This was followed in 36 patients by high dose
melphalan with autologous bone marrow rescue. Twenty-six patients also received irradiation to the site of
primary tumour.
The Rapid VAC regimen was well tolerated and largely administered as an out-patient. There was one toxic
death which occurred 2 months after high dose melphalan due to a combination of infection and possible
anthracycline cardiomyopathy. Stages were, (Intergroup Rhabdomyosarcoma Study (IRS) system) Group,
Group II - four patients, Group III - 27 patients and Group IV - 12 patients; International Society of
Paediatric Oncology (SIOP) staging, Stage I-ll, Stage 11-13, Stage III-7, Stage IV- 12. Actuarial survival at
5 years for all stages is 57% and event free survival 44%. For patients with non-metastatic diseases, 62% and
53% respectively.
This treatment strategy utilises the philosophy of rapid drug delivery with high dose consolidation and
enables all chemotherapy to be finished within a 4 month period. In general, a conservative approach was
applied to both radiation and surgery to minimise late sequelae related to these treatment modalities.
Although the small number of high risk patients in this study limits conclusions regarding efficacy in these
subgroups the overall results with this regimen appear to be comparable to that with other approaches.
For over a decade the management of childhood rhab-
domyosarcomas has been based on prolonged chemotherapy
with cyclophosphamide based regimens (King et al., 1981;
Hays, 1982; Kingston et al., 1983). The duration of treatment
has been reduced to 1-2 years in most large studies but for
patients with non localised disease this is rarely less than 9 to
12 months. The feasibility of delivering a single high dose of
an alkylating agent, melphalan, using autologous bone mar-
row rescue led to the introduction of this treatment for these
patients at the Royal Marsden. From 1981-89, this was the
standard treatment for such patients. The backbone of the
treatment is weekly administration of moderate dose VAC
which, in most patients, is followed by high dose melphalan.
The decision to use radiotherapy or surgery is individualised
as is inevitable with a tumour which affects many different
primary sites. In this decision the patient's age, tumour
histology and initial extent of disease is taken into consid-
eration.
The aim of this treatment strategy was to intensify and
shorten chemotherapy in the hope that rapid drug delivery
and high dose intensity would improve the response at the
primary site and control of micrometastatic disease. It was
hoped that in some patients, particularly the younger ones,
radiation treatment with its attendant sequelae on growth
might be avoided.
Patients and methods
Forty-three patients without complete resection of primary
tumour have been treated with the Rapid VAC regimen.
Their initial stage and site are summarised on Table I. The
histopathological subgroup was embryonal in 29, alveolar in
six, undifferentiated in six, pleomorphic in one and botryoid
in one.
The commonest primary sites were head and neck, limb/
trunk and orbit. Patients ages ranged from 8 months to 21
years with a median of 5 years.
The treatment strategy is summarised in Figure 1. Drug
doses in Rapid VAC are cyclophosphamide 400 mg m-2, vin-
cristine 1.5 mgm-2, adriamycin 40 mg m-2. Courses were
given at weekly intervals providing the neutrophil count was
> 1.0 x 109 - 1 and platelet count > 100 x I09 1-'. Treatment
was given within 8 weeks in 46% of patients and within 10
weeks in a further 30%. In 10% treatment was delayed for
> 10 weeks because of recurring prolonged marrow suppres-
sion. In the remaining patients treatment was changed due to
poor response before completion of the Rapid VAC regimen
and in one patient treatment was terminated prematurely due
to unacceptable marrow suppression and mucositis.
High dose melphalan was given 6-8 weeks after comple-
tion of Rapid VAC. The dose ranged from 140-220 mg m-2
and unpurged, non cryopreserved marrow was reinfused at
12-24 h after melphalan (Figure 2). Cyclophosphamide 'pri-
ming' was used routinely with 300mgm2i.v. given 1 week
prior to melphalan. This has been shown to significantly
reduce intestinal toxicity and may shorten the period of
neutropaenia (Selby et al., 1987; Hedley et al., 1978).
Eight patients with either metastatic disease or refractory
primary tumour after Rapid VAC received second line chem-
otherapy with etoposide ± cisplatin and five of these were
given high dose carboplatin in combination with melphalan
as megatherapy (Pinkerton et al., 1989).
Response to therapy
Overall, using multimodality treatment, complete remission
was achieved in 37 patients (86%). In 16/39 patients with
measurable disease after initial surgery a complete response
was achieved with combination chemotherapy (VAC -
HDM) alone, with delayed surgery, in five and irradiation in
eight. In two patients there was a residual imageable mass
which remained stable for > 12 months. The response to
initial Rapid VAC alone was 78% (66% PR; 12% CR) with
disease re-evaluation at 10-12 weeks.
High dose melphalan was not given to 14 patients. In three
Correspondence: C.R. Pinkerton, Paediatric Oncologist, Children's
Unit, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2
5PT, UK.
Received 9 July 1990; and in revised form 17 April 1991.
Br. J. Cancer (1991), 64, 381-385 '." Macmillan Press Ltd., 1991382 C.R. PINKERTON et al.
Table I Details of IRS stage, site ofprimary and metastatic disease and pathological subtype
Pathology
Group (IRS) Primary Embryonal Alveolar Undifferentiated Pleomorphic Botryoid
Forearm 1
Skull 1
Foot 1 2 2 0 0 0
Mastoid 1
III Orbit 8 Bladder 2
Face 3 Pelvic 1
Nasopharynx 3 Testis 1 20 2 4 1 0
Neck 2 Liver I
Chest Wall 1
Abdomen 2
Vagina 3
IV Abdominal
wall 2 Perineum 2
Testis 2 Forearm 1
Trunk 1 Abdomen 1 7 2 2 0 1
Vagina 1
Nasopharynx 1
Pelvis 1
Metastases Lung 6
Bone 3
Marrow 3
Innial surgery
- Resection -
or
biopsy
VCR 1.5 mg mrl' ,
ADR 40 mg ne weekly x 6
CP 400 mg m' J
Micro
aheol
Melphahan
200 mg mw
followed by
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marrow
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kw htstology
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Figure 1 Outline of strategy using Rapid VAC, mel
delayed surgery and irradiation. (VCR = vincristine;
riamycin; CP = cyclophosphamide).
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Figure 2 Outline ofprotocol for high dose melphalai
phosphamide priming.
this was because of refractory disease and progr
had orbital primaries regarded as curable with
radiotherapy alone. The parents refused HDM it
The others had small primaries with a rapid
VAC.
Sixteen were electively not irradiated. Five o
metastatic disease at presentation. Eight with Grc
disease achieved complete response with chemoti
and no further therapy was judged necessary.
initial PD. Of the 14 non-metastatic patients wi
irradiated there have been two local relapses al
currently in second complete remission after fur
therapy and radiotherapy.
Toxicity
The Rapid VAC regimen was well tolerated
majority of patients was administered on an
basis. Myelo-suppression was the main toxicity
eral only the first 2-3 courses could be giver
intervals. This was followed by a 14 day break
further two courses were given followed by 1-2
prior to the final courses. In 35% of patients hospital admis-
Surgery sion was required for intravenous antibiotics during a period
of febrile neutropaenia. Mucositis occurred in 10% of pa-
tients but was only rarely a cause of delaying treatment. No
intestinal or hepatic toxicity was noted. One patient was
erroneously given eight courses of Rapid VAC in quick
Noresidua disease succession and developed cardiac failure due to probable
CR anthracycline cardiotoxicity. She subsequently had a heart
treatmen transplant and remains well in remission. The one toxic death
Nofurtrtreatment in the study occurred 2 months following high dose mel-
phalan, shortly after a hospital admission for sepsis. Autopsy
Iphalan with revealed a non specific pneumonitis and cardiac changes
ADR = ad- consistent with antracycline administration. The precise con-
tribution of the latter to her sudden death is unclear, but is
assumed to have been of some significance. A minority of
long term survivors from this regimen have been followed-up
with ECHO cardiographs and, of the first 15 studied, there
0 has been no evidence of any myocardial dysfunction.
m The toxicity associated with the single course of high dose
'narrow melphalan was as has been previously described in children
with the anticipated diarrhoea, mucositis and septic neu-
tropaenia. Hepatic veno-occlusive disease was not seen. The
n and cyclo- time to recover >0.5 x 109 I-l neutrophils ranged from 12 to
22 days and time to >50 x 09 I-' platelets from 12 to 51
days. The duration of hospital admission for the procedure
ranged from 15 to 35 days.
The efficacy of high dose melphalan given at this stage was
ression. Five difficult to evaluate. In many patients a further reduction in
h VAC and residual measurable tumour may have been due to a continu-
a four cases. ing response to Rapid VAC rather than the high dose con-
response to solidation therapy. With this qualification, however, further
tumour reduction was noted in 14/24 patients receiving
f these had megatherapy and included eight complete responses.
Dup II or III
ierapy alone
Three had
ho were not
nd both are
ther chemo-
and in the
out-patient
and in gen-
a at weekly
and then a
week break
Outcome
The outcome, stage by stage, is shown in Table II with
details of the relapse sites. In IRS Group II two out of four
have relapsed, in Group III, 10/27 have relapsed or pro-
gressed and four of these are in second complete remission.
In Group IV, patients eight out of 12 have relapsed.
The actuarial survival of the two largest subgroup of
patients is shown in Figure 3. The progression free survival is
shown in Figure 4.
Details of relapse sites are given in Table II. For the
largest subgroup - IRS Group III - 40% of patients that
relapsed are in second CR, resulting in a survival rate at 3
years of 67%. Only 20% of those with metastatic disease at
presentation survive.RAPID VAC REGIMEN FOR SOFT TISSUE SARCOMA 383
TableII OutcomeinrelationtoIRSstage. Theinitialsiteofdiseaseandsite(s)
of relapse are also listed
IRSgroup Number ofrelapses Initial site Relapse site
II 2/4 Mastoid Local + CNS
Forearm Local + abdominal nodes
III 10/27 Chin
Nasopharynx Initially
Abdomen refractory
Vagina
Face Local + lung
Trunk Lung
Orbit 1
Orbit
Pharynx
Abdomen
IV 8/12 Multiple Initially refractory 2
Local + distant site 2
Distant sites 4
aIn second CR after further treatment.
100 The final results of this study are not available but it appears
that although overall survival is higher than in IRS 2, this X,% ...... 90 1. does not appear to be due to the additional chemotherapy
80 (Crist et al., 1989). ....... 1 Between IRS 1 and IRS 4 there has been a small but
70 significant improvement in overall survival, particularly as-
60 111 sociated with the intensification of treatment for certain high
risk subgroups, for example, the parameningeal primary site
50 ....... (Maurer et al., 1988). In the earlier studies in particular this
40 has involved aggressive, often mutilating surgery, and early, ......................... wide field irradiation to initial tumour bulk.
30 The other major cooperative group, SIOP, has adopted a
20 different strategy to the IRS. The STOP philosophy is based IV on intensive initial chemotherapy with delayed surgery and
10 radiation. The nature of both surgery and radiotherapy
0 ..... depend upon the initial response to chemotherapy. Where
0 1 2 3 4 5 complete remission is achieved using chemotherapy alone,
Time since treatment (years) radical surgery and radiotherapy are avoided. In this way it
was hoped to reduce late sequelae of the latter treatment
gure 3 Survival for IRS Group III and IV patients. modalities, without compromising cure rate (Flamant et al.,
1985). The initial SIOP study was based on similar drugs to
those used in the IRS studies, but recently, ifosfamide has
100 been introduced (Flamant et al., 1987). There are indications
that this agent may have advantages over cyclophosphamide
90 . in terms of initial response rate (Bramwell et al., 1986;
80- .in Treuner et al., 1987). The SIOP approach has been followed
by the German CWS studies where vincristine, actinomycin,
70- adriamycin and ifosfamide are given as initial induction
60- . ~n_ chemotherapy and both surgery and radiotherapy are re-
duced to a minimum (Treuner et al., 1987). The overall
50- survival rates are currently comparable between the Euro-
40- .... ~ ~ ~ -~- pean and the American studies, although relapse free survival
40 111 is higher with the more aggressive IRS strategy. There is a
30- continuing debate about outcome in various subgroups,
made complex by different staging systems (Donaldson et al.,
20 .............................................................................................................. 20 ...1984; Lawrence et al., 1984; Pizzo et al., 1987; Voute et al.,
10- IV 1986). Current cooperative analyses are hoped to resolve this
(Rodary et al., 1987). A fundamental issue to be clarified is
0 - . lI whether a higher local relapse rate can be compensated for
0 1 2 3 4 5 by cure with second line chemotherapy, radiotherapy and
Time since treatment (years) surgery.
gure 4 Progression free survival for IRS Group III and IV A prerequisite for success in rhabdomyosarcoma is
tients. effective initial chemotherapy which achieves high, genuinely
'complete' responses. The traditional VAC regimen is clearly
unable to do this in a significant proportion of patients.
Innovative chemotherapeutic strategies are few. The pro-
cussion posed IRS 4 study considers alternative drug combinations;
vincristine + low dose melphalan, ifosfamide + VP16 and
ce the inception of the IRS a series of randomised inves- ifosfamide + adriamycin. These combinations, however, use
Ltions have demonstrated the need for intensified treat- conventional drug doses and the traditional 21 day schedules.
it in certain subgroups and the feasibility of a reduction Bearing in mind the results in IRS III it seems unlikely that
intensity for others. IRS 3 evaluates the role of this approach will be of major benefit. There is evidence of
nsification with etoposide and cisplatin in addition to the activity of melphalan in the xenograft model (Houghton et
ic vincristine, actinomycin, cyclophosphamide regimen. al., 1985) and also in phase II studies using low dose mel-
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phalan (Belasco et al., 1987). The feasibility of giving
between 200-240 mg m-2 of melphalan and overcoming
the problem of profound myelo-suppression by autologous
bone marrow rescue has been clearly demonstrated in child-
ren, particularly with neuroblastoma. The efficacy of high
dose melphalan in refractory rhabdomyosarcoma has been
demonstrated in a number of small studies (Bagnulo et al.,
1985).
The strategy of rapid dose delivery with high dose intensity
requires evaluation (DeVita, 1986). Dose intensity has been
demonstrated to correlate with initial response rates in some
adult tumours (Hryniuk et al., 1986). Rapid drug delivery,
minimising the interval between tumour exposure to active
agents has been used in malignant germ cell tumours, non
Hodgkin's lymphoma, and also, recently, in neuroblastoma
with encouraging results (Pearson et al., 1988; Hann et al.,
1988; Horwich et al., 1989). With the doses used in the Rapid
VAC regimen several courses of chemotherapy can be given
within a short period. Although the initial complete response
rate with Rapid VAC is lower than that reported in the SIOP
and CWS studies, the initial evaluation is after only 10-12
weeks rather than 3-4 months. The percentage of initially
refractory patients with the Rapid VAC regimen is com-
parable to that in other studies i.e. 10-20%. In one study
where response in Groups III/IV patients was assessed after
-8 weeks CVAct, CR + PR rate = 54% (Carli et al., 1988).
For these two groups the response rate with Rapid VAC was
78% suggesting there may be some advantage to this sched-
ule.
The early introduction ofmelphalan allows the administra-
tion of a high total dose of effective alkylating agent in a
minimum period of time. The overall duration of therapy is
reduced to approximately 3 months which has clear advan-
tages in terms of patient acceptability. The toxicity of the
high dose melphalan is not worse than that associated with
either the high dose IVAD regimens containing 9 g of ifos-
famide or the IRS 3 VAC + platinum and etoposide. There
was a single toxic death associated with the melphalan
regimen but it was generally well tolerated and the duration
of hospital stay was not particularly long.
Within the limitations of patient numbers, the overall out-
come with this approach is encouraging. Fifty-five per cent
actuarial progression free survival at 3 years for IRS Group
III patients is comparable to that reported by other groups
with up to 2 years of VAC chemotherapy (IRS 1 42%)
(Maurer et al., 1988). When analysed on the basis of SIOP
staging which emphasises regional extension of primary tu-
mour progression free survival for Stage II patients is again
55% (survival 62%). This is similar to the result with SIOP
regimens using IVA, as in the SIOP regimen MMT '84 (50%
at 3 years). The salvage rate in MMT '84 appears higher with
67% surviving at 3 years and may be due to the absence of
initial irradiation in all these cases.
The combination of etoposide and cisplatin is active in
relapsed sarcomas (Carli et al., 1987; Castello et al., 1988)
and it might be possible to incorporate these drugs in a rapid
dose delivery schedule combined with the Rapid VAC regi-
men. The failure of the IRS to demonstrate benefit from the
addition of these drugs may reflect the small dose of etopo-
side used and the overall drug scheduling.
The effectiveness in another high risk group - the para-
meningeal tumours - is unclear due to the small number but
with HDM after conventional VAC only 30% DFS has been
reported (Kingston et at., 1985), despite aggressive radio-
therapy. It is possible that delay in the timing of the latter
may be of significance and outcome appears to be better in
both STOP and IRS studies with early radiotherapy (before 8
weeks). This is the one tumour site where the strategy of
delaying irradiation until after prolonged chemotherapy is
inappropriate.
Results in patients with metastatic disease are disappoint-
ing and no significant benefit was apparent using this ap-
proach, with a survival of only 25%. The current SIOP
MMT '89 regimen includes an intensive multiagent regimen
for metastatic disease with pulses of carboplatin/epirubicin;
ifosfamide/actinomycin; ifosfamide-etoposide. In that study,
dose escalation with high dose carboplatin, busulphan and
thiotepa, is being evaluated in refractory patients with a view
to future incorporation in a first remission regimen.
There is understandable concern about the late effects of
high dose alkylating agent administration. It is not clear,
however, that a single dose of 200 mgm-2 of melphalan is
worse than 54 g of ifosfamide, which is delivered in six
courses of the current SIOP regimen, or the 10 g of cyclo-
phosphamide delivered in 12 months of the IRS 3 protocol
(Watson et al., 1985; Byrne et al., 1987). The exact risk of
infertility or second malignancies after a single high dose of
melphalan in children is not clear and requires further study
(Hartmann et al., 1984). Adverse effects on endocrine func-
tion have been suggested but these are yet to be confirmed in
larger series (Kellie et al., 1987).
The occurrence of one major cardiotoxicity in 43 patients
and possible cardiac contribution to toxic death in one other
is of concern but the former case was a protocol violation
who received eight courses in 10 weeks. A detailed car-
diological follow-up is currently underway to try and clarify
this issue and to date has not revealed a high incidence of
cardiac toxicity.
It would seem prudent, however, to consider replacement
of adriamycin with actinomycin or alternate these two agents
in any future regimen.
This study was started at a time when 2 years ofVAC plus
irradiation was used for IRS Group II cases. It is possible
that Rapid VAC alone without melphalan is sufficient
chemotherapy for some of these patients. With the IVA
regimen (SIOP MMT '84) irradiation was omitted in the
majority ofpatients but the local relapse rate was higher than
in IRS studies. Whether the use of melphalan could reduce
this local relapse rate is unproven, and the late effects of this
treatment modality may be different but no less significant
than irradiation. The SIOP group has chosen to increase the
dose of ifosfamide in these patients which may also have its
own late sequelae.
Only six of the ten non metastatic patients who were not
irradiated received melphalan, so no conclusion can be drawn
regarding the effect of this procedure on local control.
For some patients with regional disease (mainly IRS
Group III or SIOP Stage II) it is likely that the
intensification of chemotherapy in this study allowed omis-
sion or reduction of wide field irradiation - of particular
importance for the younger child and those with
genitourinary and head and neck primaries.
In conclusion, the Rapid VAC/melphalan regimen is a well
tolerated treatment programme generally requiring only 3-4
weeks of hospital admission. Encouraging results were seen
in standard risk patients but alternative strategies are still
required for high risk patients such as those with node
positive, parameningeal or metastatic disease. This approach
has the advantages ofbrevity and, possibly, increased efficacy
due to rapid dose delivery and high dose intensity. The
increasing availability of haematological growth factors
(Metcalf et al., 1989) or perhaps the use of additional
peripheral stem cell harvest (Watanabe et at., 1989) could
further reduce the duration of hospitalisation and treatment
morbidity. Moreover, the former could facilitate the adminis-
tration of VAC in the prescribed time.
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